Longboard Pharmaceuticals, Inc. Common Stock
LBPH
LBPH was delisted on the 29th of November, 2024.
19 hedge funds and large institutions have $26.6M invested in Longboard Pharmaceuticals, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 3 closing their positions.
16% more capital invested
Capital invested by funds: $22.9M → $26.6M (+$3.64M)
5% less funds holding
Funds holding: 20 → 19 (-1)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$239K |
| 2 |
IHAM
Integral Health Asset Management
New York
|
+$195K |
| 3 |
Millennium Management
New York
|
+$41.9K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$591 |
| 5 |
Wells Fargo
San Francisco,
California
|
+$81 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$784K |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$572K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$84K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$29.9K |
| 5 |
BlackRock
New York
|
-$10.5K |
LBPH Hedge Fund Activity: Q3 2022 in Review
19 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Longboard Pharmaceuticals, Inc. Common Stock (LBPH) for Q3 2022, worth a combined $26.6M — up 16% from $22.9M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of LBPH and 2 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 5 added.
The largest buyer was Geode Capital Management, adding an estimated $239K. The largest seller was Citigroup, cutting an estimated $784K.
- 19 institutional investors held Longboard Pharmaceuticals, Inc. Common Stock (LBPH) as of Q3 2022, down from 20 in Q2 2022.
- Funds reported $26.6M of Longboard Pharmaceuticals, Inc. Common Stock stock for Q3 2022, up 16% quarter-over-quarter.
- 2 funds opened new Longboard Pharmaceuticals, Inc. Common Stock positions in Q3 2022 and 3 closed out, a net change of -1 holder.
- The largest Longboard Pharmaceuticals, Inc. Common Stock buyer in Q3 2022 was Geode Capital Management, an estimated $239K added.
- The largest Longboard Pharmaceuticals, Inc. Common Stock seller in Q3 2022 was Citigroup, an estimated $784K sold.
Based on aggregated 13F filings for Q3 2022.